title: So FCR, so good.
abstract: In this issue of Blood, Rossi et al show that certain predictive biomarkers are able to identify a subgroup of patients with chronic lymphocytic leukemia (CLL) who have an exceptionally good outcome following front-line therapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR).
authors.affiliation: THE ROYAL MARSDEN HOSPITAL AND BIOMEDICAL RESEARCH CENTRE.
authors.forename: Claire
authors.initials: C
authors.lastname: Dearden
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D008297:Male; D058496:Smith-Magenis Syndrome